Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting

Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS

Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). While tofersen did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), trends favoring tofersen were seen across multiple secondary and... More

Biogen (BIIB) option implied volatility near low end of range

Biogen (NASDAQ: BIIB) 30-day option implied volatility is at 35; compared to its 52-week range of 32 to 121.

Biogen (BIIB) Survey Data Conflicts with Bullish View, Piper Sandler Beginning to Get Concerned

Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $460.00 price target on Biogen (NASDAQ: BIIB) after conducting a survey in September, that conflicts with bullish share projections.

The analyst stated "the massive patient/caregiver demand we had anticipated has not materialized... More

Biogen (BIIB) Expert Call Highlights Difficulties with Aduhelm Launch, Numbers Need to Come Down - Jefferies

Jefferies analyst Michael Yee reiterated a Buy rating and $400.00 price target on Biogen (NASDAQ: BIIB) after hosting a KOL call to discuss the Aduhelm launch. The KOL had 6 pts already on drug and had a few that were reimbursed by MACs in NY.

The... More

New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

Biogen Inc. (Nasdaq: BIIB) today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). The results, which demonstrate that patients treated with Biogens portfolio of MS therapies mount an effective antibody response to COVID-19 vaccination, are being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)... More

Biogen (BIIB) PT Lowered to $447 at Morgan Stanley

Morgan Stanley analyst Matthew Harrison lowered the price target on Biogen (NASDAQ: BIIB) to $447.00 (from $455.00) while maintaining a Overweight rating.... More